European Journal of Integrative Medicine最新文献

{"title":"East Asian herbal medicine as an add-on to antipsychotics in schizophrenia spectrum disorders accompanied by agitation: a systematic review and meta-analysis","authors":"Chan-Young Kwon ,&nbsp;Ji-Won Kim ,&nbsp;Ji-Won Oh ,&nbsp;Hye-Li Jeon ,&nbsp;Min-Jae Kim ,&nbsp;Kyoung-Eun Lee ,&nbsp;Boram Lee ,&nbsp;Pyung-Wha Kim ,&nbsp;Yujin Choi","doi":"10.1016/j.eujim.2025.102583","DOIUrl":"10.1016/j.eujim.2025.102583","url":null,"abstract":"<div><h3>Introduction</h3><div>Agitation is a frequent and disrupting symptom of schizophrenia spectrum disorders (SSDs) that can be difficult to manage with antipsychotic treatment alone. East Asian herbal medicine has been explored as a complementary therapy, but its effectiveness remains unclear. This review aimed to evaluate the effectiveness and safety of East Asian herbal medicine as an add-on therapy to antipsychotics compared to antipsychotics alone in the management of agitation in patients with SSDs.</div></div><div><h3>Methods</h3><div>Ten sources including eight databases (PubMed, EMBASE, CENTRAL, CNKI, CiNii, KISS, ScienceON, OASIS) and two additional sources (WHO ICTRP, JSOM website) were searched to January 2025. Randomized controlled trials (RCTs) comparing East Asian herbal medicine added to antipsychotics with antipsychotics alone in patients with SSDs accompanied by agitation were included. The primary outcome was the agitation symptoms measured using standardized scales (CMAI, PANSS-EC, or BPRS-EC), where lower scores indicate reduced agitation. Random-effects meta-analyses were performed. Risk of bias was evaluated using Cochrane RoB 2. The certainty of evidence for each outcome was assessed using the GRADE approach.</div></div><div><h3>Results</h3><div>Seven RCTs (n = 639) were included. Meta-analysis showed that East Asian herbal medicine added to antipsychotics significantly improved agitation symptoms (SMD −0.88 [95 % CI −1.26, −0.49]; I²=74 %), reduced adverse events (RR 0.44 [95 % CI 0.34, 0.57]; I²=0 %), and improved overall schizophrenia symptoms (SMD −1.99 [95 % CI −3.11, −0.86]; I²=68 %). Risk of bias was assessed as “some concerns” in all studies, mainly because of absence of allocation concealment reporting, placebo controls, and pre-registered protocols. Certainty of evidence was rated as moderate for agitation (downgraded for risk of bias) and low for secondary outcomes (downgraded for risk of bias and imprecision).</div></div><div><h3>Conclusions</h3><div>East Asian herbal medicine may improve agitation and reduce adverse events in SSDs when combined with antipsychotics. Large effect sizes warrant caution regarding potential small-study effects and methodological limitations. Future research should use rigorous double-blind placebo-controlled designs, standardized formulations, extended follow-ups, and diverse populations.</div></div><div><h3>Registration</h3><div>Protocol of this review was registered via PROSPERO (CRD42025643106)</div></div><div><h3>Funding</h3><div>Ministry of Health &amp; Welfare, Republic of Korea [grant number RS-2024-00442840]</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"81 ","pages":"Article 102583"},"PeriodicalIF":1.7,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145536861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Saengmaeksan (Shengmai-san) for arterial stiffness in middle-aged women: A feasibility study","authors":"Nahyun Cho ,&nbsp;Jungah Uhm ,&nbsp;Changsop Yang ,&nbsp;Hiroshi Miyashita ,&nbsp;Hobin Moon ,&nbsp;Jungtae Leem","doi":"10.1016/j.eujim.2025.102581","DOIUrl":"10.1016/j.eujim.2025.102581","url":null,"abstract":"<div><h3>Introduction</h3><div>Aging causes significant vascular alterations, increasing susceptibility to arterial stiffness and cardiovascular diseases. Interest in complementary and alternative medicines, such as modified Saengmaeksan (mSMS), a traditional East Asian herbal formulation, has intensified given its benefits in mitigating arterial stiffness. However, robust clinical evidence supporting it's efficacy remains limited. This feasibility study aimed to explore the applicability, safety, and potential short-term effects of mSMS on pulse wave indices associated with arterial stiffness in a real-world clinical setting.</div></div><div><h3>Methods</h3><div>This prospective single-arm feasibility study enrolled 30 patients aged 19–75 years who underwent mSMS for 4 weeks. The second-derivative photoplethysmography (SDPTG), heart rate variability, augmentation index, and blood pressure-related indices were measured at baseline, after 2 weeks, and after 4 weeks of treatment. The body mass index, Measure Yourself Medical Outcome Profile, and Patient Global Impression of Change scores were also obtained. Blood tests were conducted to assess the safety profile of mSMS.</div></div><div><h3>Results</h3><div>High adherence (mean intake of 94.4 %) and full data completeness were achieved. After 4 weeks of mSMS treatment, exploratory analyses showed significant improvements in SDPTG vascular age (mean change: −15.90 years, <em>p</em> &lt; 0.001) and augmentation index (<em>p</em> &lt; 0.01), with no serious adverse events. Patient-reported outcomes also showed improvement. The study suggests that mSMS may have the potential to improve vascular function and could offer benefits in middle-aged women, potentially independent of menopausal status.</div></div><div><h3>Conclusion</h3><div>mSMS administration was feasible and well-tolerated in middle-aged women in a clinical setting. However, due to the single-arm design and small sample size, definitive conclusions cannot be drawn. These results support the need for larger, controlled clinical trials to further evaluate the clinical efficacy and target population of mSMS in preventing cardiovascular problems.</div></div><div><h3>Registration</h3><div>Public Institutional Review Board Designated by the Ministry of Health and Welfare (authorization number: P01–201,711–21–020). Research Information Service of South Korea (KCT0002648).</div></div><div><h3>Funding</h3><div>the National Development Institute of Korean Medicine, funded by the Ministry of Health and Welfare, Republic of Korea [grant number HI16C0275]; the National Research Foundation of Korea, funded by the Korea government [grant number RS-2022-NR072366]; the Korea Health Technology Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea [grant numbers RS-2023-KH139333, RS-2023-KH139598].</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"81 ","pages":"Article 102581"},"PeriodicalIF":1.7,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145536860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based ranking of herbal medicines for hypertension management: A systematic review and network meta-analysis of randomized controlled trials","authors":"Alireza Malektojari ,&nbsp;Parsa Ghaedzade Khamiri ,&nbsp;Fatemeh Bagheri ,&nbsp;Najmeh Baniasadi ,&nbsp;Laya Khajooei ,&nbsp;Mahdieh Roohi ,&nbsp;Mojgan Bolandparva ,&nbsp;Atena Ghorbani ,&nbsp;Mohammad Mehdi Noormohammadi ,&nbsp;Nazanin Hooshyari ,&nbsp;Ani Orchanian-Cheff ,&nbsp;Fateme Afra ,&nbsp;Raziyeh Mirzadeh ,&nbsp;Zahra Mafi ,&nbsp;Raha Paozki ,&nbsp;Abbas Dehghan ,&nbsp;Sara G. Khosrowshahi","doi":"10.1016/j.eujim.2025.102582","DOIUrl":"10.1016/j.eujim.2025.102582","url":null,"abstract":"<div><h3>Introduction</h3><div>Hypertension affects over 116 million adults in the United States and &gt;1 billion globally, substantially contributing to cardiovascular morbidity. Herbal therapies have emerged as potential complementary treatments for blood pressure management. To the best of our knowledge, this study is the first systematic review with network meta-analysis (NMA) aimed at ranking the most effective herbal therapies for lowering blood pressure.</div></div><div><h3>Methods</h3><div>We systematically searched MEDLINE, Embase, Cochrane CENTRAL, and Cochrane Database of Systematic Reviews (CDSR), selecting randomized controlled trials (RCTs) enrolling hypertensive and prehypertensive adults that compare herbal medicine interventions to placebo, usual care, or against each other. We used the Cochrane RoB 2 tool to assess the risk of bias. We performed frequentist random-effects network meta-analyses and summarized effects as mean differences (MD) with 95 % confidence intervals (CI). We evaluated the certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.</div></div><div><h3>Results</h3><div>A total of 47 RCTs involving 3,559 patients met prespecified eligibility criteria. Our NMA indicates that Celery (Apium graveolens) reduces systolic blood pressure (SBP) by (MD -10.9 [95 % CI -17.6 to -4.3], p-value=0.001) with high certainty of evidence. Caucasian whortleberry (MD -16.2 [95 % CI -22.9 to -9.5], p-value&lt;0.0001), Roselle (MD -7.7 [95 % CI -11.9 to -3.5], p-value=0.0003), and Garlic (MD -6.0 [95 % CI -8.8 to -3.2], p-value&lt;0.0001) probably reduce SBP with moderate certainty. No serious adverse events were reported.</div></div><div><h3>Conclusion</h3><div>There is moderate to high certainty that Celery and Caucasian whortleberry were the most effective treatments for reducing blood pressure, among included herbal medicines, in hypertensive and pre-hypertensive patients. Additional long-term, large-sample RCTs are warranted to refine dosing, safety, and sustained effects. Clinicians should interpret results cautiously, given heterogeneity and limited direct evidence for some herbs.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"81 ","pages":"Article 102582"},"PeriodicalIF":1.7,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of dietary chitosan on serum lipid levels: A systematic review and meta-analysis of randomised controlled trials","authors":"Yenn Ye Yap ,&nbsp;Zoriah Aziz","doi":"10.1016/j.eujim.2025.102578","DOIUrl":"10.1016/j.eujim.2025.102578","url":null,"abstract":"<div><h3>Introduction</h3><div>Hypercholesterolaemia is a key risk factor for cardiovascular diseases. Although chitosan is known for its weight loss properties, its effects on serum lipid levels remain unclear. This study aimed to evaluate the effects of dietary chitosan on serum lipid levels, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and total cholesterol (TC).</div></div><div><h3>Methods</h3><div>A comprehensive search of electronic databases including Medline, Scopus, Cochrane Central Register of Controlled Trials, Web of Science, and CINAHL Complete was conducted. Randomised controlled trials (RCTs) were eligible if they assessed the effects of chitosan on LDL-C, HDL-C, TG, and TC in patients with hypercholesterolaemia or dyslipidaemia at baseline. We assessed the risk of bias of included studies, pooled the results using a random-effects model, and evaluated the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.</div></div><div><h3>Results</h3><div>We included 16 RCTs involving a total of 1327 participants. The meta-analysis showed chitosan was associated with statistically significant reduction of LDL-C (WMD: -0.16 mmol/L, 95% CI: -0.23 to -0.10), TG (WMD: -0.04 mmol/L, 95% CI: -0.08 to -0.01), and TC (WMD: -0.25 mmol/L, 95% CI: -0.36 to -0.14), while the effect on HDL-C was not statistically significant (WMD: 0.01 mmol/L, 95% CI: -0.02 to 0.04). Adverse events, mainly mild gastrointestinal (GI) symptoms, were reported in 11 of 16 studies, with constipation being the most common. Subgroup analyses indicated variations in treatment effects based on chitosan dosage, and sensitivity analysis revealed that the TG-lowering effect of chitosan was statistically unstable.</div></div><div><h3>Conclusion</h3><div>Chitosan is associated with statistically significant but clinically negligible reductions in LDL-C, TG, and TC, and has no meaningful effect on HDL-C. The overall certainty of evidence was moderate for LDL-C and low for HDL-C, TG, and TC. Better-designed, larger, and longer trials are needed to confirm its safety and effectiveness as a lipid-lowering supplement.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102578"},"PeriodicalIF":1.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of Bufei granules in treatment of preserved ratio impaired spirometry: Study protocol for a randomized controlled trial","authors":"Yang Xie ,&nbsp;Yiting Li ,&nbsp;Peng Zhang ,&nbsp;Baichuan Xu ,&nbsp;Beibei Bao ,&nbsp;Zifan Cheng ,&nbsp;Tao Chen ,&nbsp;Jiansheng Li","doi":"10.1016/j.eujim.2025.102580","DOIUrl":"10.1016/j.eujim.2025.102580","url":null,"abstract":"<div><h3>Introduction</h3><div>Early identification and monitoring of preserved ratio impaired spirometry (PRISm) population and suitable intervention can reduce the incidence rate of chronic obstructive pulmonary disease (COPD) and delay the disease process. Although Traditional Chinese medicine (TCM) has been used to treat COPD for many years, few data are available for the PRISm population. This study aims to evaluate the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD.</div></div><div><h3>Methods</h3><div>This is a multicenter, randomized, double-blind, placebo-controlled trial targeting the PRISm population. One thousand one hundred PRISm patients will be randomly divided into two groups, with the experimental group receiving Bufei granules and the control group receiving placebo granules. The treatment regimen is to take one packet after meals, twice daily, for a period of two years. The main outcome is the incidence rate of COPD, and the secondary outcomes are lung function, COPD screening score, quality of life, clinical symptoms, 6-minute walking distance (6MWD), dyspnea score, biochemical indicators, and economic evaluation. Blood and urine routine tests, liver and kidney function tests, electrocardiogram, and chest computed tomography scans will be employed as safety indicators for the trial, with any adverse events occurring during the trial period being accurately recorded. The planned observation duration per patient is 2 years and will be followed up every 6 months.</div></div><div><h3>Discussion</h3><div>This study will provide evidence to assess the efficacy and safety of Bufei granules in preventing progression from PRISm to COPD. It is expected that PRISm volunteers will show a reduced incidence rate and will exhibit improved lung function and quality of life. The data will be released after the research is completed.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov registration number: NCT06375824.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"81 ","pages":"Article 102580"},"PeriodicalIF":1.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145570815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Group acupuncture following a psychedelic ketamine experience: An integrative medicine pilot study","authors":"Marjorie Navarro","doi":"10.1016/j.eujim.2025.102579","DOIUrl":"10.1016/j.eujim.2025.102579","url":null,"abstract":"<div><h3>Introduction</h3><div>There is a lack of information on bodywork, such as acupuncture, in conjunction with psychedelic medicine. The objective of this pilot study was twofold: to assess the feasibility and tolerability of acupuncture in a group setting as an integrative somatic intervention following a ketamine experience for psychospiritual growth.</div></div><div><h3>Methods</h3><div>Participants (<em>n</em> = 15) were enrolled in a group ketamine experience followed by acupuncture one hour after ketamine administration. An optional Participant Feedback Form was administered after the session; responses were reported descriptively as acceptability signals and were not analyzed as formal qualitative data. The Experienced Integration Scale (EIS) was administered within 72 h after the intervention and again after 3 months.</div></div><div><h3>Results</h3><div>Of 88 people who requested an eligibility review, 17 were enrolled, filling the study in 20 days. Fifteen attended their scheduled sessions, yielding an 88% retention rate. Initial EIS scores ranged from 45% to 100% (mean 74%), with follow-up scores obtained from 6 participants after 3 months. Feedback from 5 participants described the acupuncture as grounding, calming, and valuable, with one suggesting more time for treatment. Together, these findings suggest that acupuncture after a ketamine experience is feasible and well-tolerated in healthy volunteers seeking psychospiritual growth.</div></div><div><h3>Conclusion</h3><div>Participant enrollment and retention rates show substantial patient interest in utilizing acupuncture and sound meditation to support psychedelic therapy. Further research is warranted to explore the potential benefits of acupuncture in conjunction with psychedelic therapy. Such research may inform care for individuals who are currently using these therapies separately, as well as those seeking more integrated approaches.</div></div><div><h3>Registration</h3><div>The study is registered at the United States Clinical Trial Registry (NCT06070090).</div></div><div><h3>Funding</h3><div>No funding agencies in the public, commercial, or not-for-profit sectors.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102579"},"PeriodicalIF":1.7,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of aromatherapy on stress, anxiety, fatigue, and sleep quality among frontline hospital nurses: A systematic review and meta-analysis","authors":"Linfang Xu ,&nbsp;Yanan Deng ,&nbsp;Lan Zeng ,&nbsp;Ruben Martin-Payo ,&nbsp;Wei Peng ,&nbsp;Chen Qiu ,&nbsp;Keqi Chen ,&nbsp;Fengying Zhang","doi":"10.1016/j.eujim.2025.102577","DOIUrl":"10.1016/j.eujim.2025.102577","url":null,"abstract":"<div><h3>Introduction</h3><div>Nurses experience a range of occupational stressors, including night shifts and excessive workloads. These factors significantly increase the likelihood of nurses developing chronic stress, anxiety, fatigue, and sleep disorders. Although numerous studies have proposed aromatherapy interventions as potential strategies to alleviate these health concerns, the evidence regarding their effectiveness remains inconclusive. This study aims to evaluate the effectiveness of aromatherapy on stress, anxiety, fatigue, and sleep disorders among nurses, and identify key factors for effective programs.</div></div><div><h3>Methods</h3><div>We systematically searched six electronic databases, supplemented by manual searches of Google Scholar and reference lists. The search covered the period from the inception of each database up until March 2025. Two researchers independently performed study selection and data extraction. The risk of bias of the included studies was evaluated using the RoB 2.0 tool. The quality of evidence for each outcome was graded using the GRADE framework. A random-effects model was used to perform the meta-analysis. Subgroup analysis was conducted to identify potential moderating variables.</div></div><div><h3>Results</h3><div>A total of 19 studies were included in this systematic review, 12 of which were RCTs. Meta-analysis results indicated that aromatherapy significantly alleviated stress (SMD= -0.74, 95 % CI [-1.12, -0.35], <em>Z</em> = 3.76, <em>P</em> = 0.0002) and fatigue symptoms (SMD = -0.76, 95 % CI [-1.10, -0.42], <em>P</em> &lt; 0.0001) among nurses. Short-term interventions (≤1 week) produced a larger effect size (SMD =-0.80, 95 % CI [-1.47, -0.14], <em>P</em> = 0.02) than longer-term interventions (&gt;1 week) (SMD= -0.61, 95 % CI [-0.95, -0.26], <em>P</em> = 0.0006), possibly due to olfactory adaptation or metabolic regulation. In contrast, the overall effect on anxiety reduction was not statistically significant (SMD =-0.89, 95 % CI [-2.21, 0.42], <em>P</em> = 0.18), and evidence regarding sleep quality improvement remained inconclusive.</div></div><div><h3>Conclusion</h3><div>Aromatherapy effectively reduces stress and fatigue in nurses, making it a valuable addition to workplace wellness programs.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102577"},"PeriodicalIF":1.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of moxibustion for diminished ovarian reserve infertility with kidney deficiency and blood stasis: a randomized controlled trial","authors":"Qianyang Zhu ,&nbsp;Katherine Thomas ,&nbsp;Sufan Ma ,&nbsp;Junling Zhou ,&nbsp;Qun Zhan ,&nbsp;Ping Zang ,&nbsp;Dan Wang ,&nbsp;Yajie Zhang ,&nbsp;Weina Zhu ,&nbsp;Huijia Li ,&nbsp;Jingjing Li ,&nbsp;Qian Shi ,&nbsp;Cairong Zhang","doi":"10.1016/j.eujim.2025.102576","DOIUrl":"10.1016/j.eujim.2025.102576","url":null,"abstract":"<div><h3>Introduction</h3><div>Diminished ovarian reserve (DOR) significantly affects female fertility and overall health. Emerging evidence suggests that moxibustion treatment improves DOR. <strong><em>Methods</em></strong>: In this multicenter randomized controlled trial, 154 patients with kidney deficiency and blood stasis–type diminished ovarian reserve (KDBSDOR) were randomized to moxibustion (76 cases) or sham moxibustion (SM) (78 cases) . Participants underwent 12 weeks of treatment followed by 12 weeks of follow-up. During the treatment period, three 7-day courses of daily (sham) moxibustion were administered, concurrently with three 28-day courses of Femoston. The primary outcome was pregnancy rate at the end of the follow-up period. Secondary outcomes included clinical efficacy, changes in hormone levels, relevant scales, and findings of ultrasound monitoring. Data were analyzed between groups based on the intention-to-treat principle.</div></div><div><h3>Results</h3><div>The pregnancy rate was higher in the moxibustion group (17.1 %) than in the sham moxibustion group (3.9 %) [risk ratio (RR) = 5.53, 95 % confidence interval (CI) (1.13, 27.00)]. The moxibustion group showed significantly greater odds of clinical efficacy than the sham moxibustion group [odds ratio (OR) = 3.32, 95 % CI (1.76, 6.25)]. Relative to the sham moxibustion group, the moxibustion group showed a greater reduction in luteinizing hormone (LH) levels and greater increases in E2, anti-Müllerian hormone (AMH), antral follicle count (AFC), and endometrial thickness (all <em>P</em> &lt; 0.05). After treatment, assessment scores decreased in both groups, with significant differences at different time points (<em>P</em> &lt; 0.001). After 12 weeks of treatment, significant between-group differences were observed in the traditional Chinese medicine clinical symptom score [mean difference (MD) = -1.405, 95 % CI (–2.031, –0.779)], menstrual integral score [MD = -0.931, 95 % CI (–1.397, –0.464)], Kupperman index [MD = -3.004, 95 % CI (–4.209, –1.800)], and self-rating anxiety scale score [MD = -3.425, 95 % CI (–4.900, –1.950)]. The patients’ KDBS physiques improved. There was no significant difference in the incidence of adverse events between the two groups (<em>p</em> = 0.209).</div></div><div><h3>Conclusions</h3><div>Moxibustion effectively improved clinical symptoms, menstruation, ovarian reserve function, hormonal balance, and pregnancy rate in patients with KDBSDOR-related infertility. This treatment is a potential alternative for women with DOR.</div><div>For a video summary of this article, see the Supplemental file 2 available online.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102576"},"PeriodicalIF":1.7,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential of curcumin in tissue engineering and nanotechnology-based drug delivery systems: A bibliometric analysis","authors":"Kaan ZIKŞAHNA ,&nbsp;Rumeysa ADIYIL ,&nbsp;Melisa ÖZKAN ,&nbsp;Murat IHLAMUR","doi":"10.1016/j.eujim.2025.102575","DOIUrl":"10.1016/j.eujim.2025.102575","url":null,"abstract":"<div><h3>Introduction</h3><div>Curcumin is widely investigated in tissue engineering and nanotechnology-enabled drug delivery, yet the rapidly expanding literature lacks a consolidated map to guide translation. To address this gap, we mapped global output, hotspots, and collaboration patterns on curcumin and aligned bibliometric trends with translational needs.</div></div><div><h3>Methods</h3><div>We conducted a Scopus-based bibliometric analysis of records published between 1997 and 2024 using a single-day snapshot (21 February 2025). A reproducible TITLE-ABS-KEY query centered on “curcumin” retrieved 12,327 documents. After retrieval, de-noising retained records that mentioned curcumin (or variants) in the title, abstract, or author keywords. We computed standard indicators (outputs, citations, subject areas, countries, institutions, authors, journals) and constructed keyword co-occurrence and collaboration networks in VOSviewer.</div></div><div><h3>Results</h3><div>Outputs increased sharply after 2016 and concentrated on pharmacology, biochemistry, materials science, and engineering. China (28.1 %), India (21.5 %), and the United States (12.6 %) led publication counts. Recurrent hotspots included bioavailability/controlled release, apoptosis/reactive oxygen species (ROS), hydrogels/nanofibers, and neuroprotection. Collaboration maps showed dense hubs around China, India, and the United States, while several regions were underrepresented.</div></div><div><h3>Conclusion</h3><div>Hotspots mirror experimental advances with nanocarriers such as PLGA, liposomes, and dendrosomes that improve curcumin stability, uptake, and therapeutic indices. Methodological transparency (single-source justification, query disclosure, de-noising) enhances reproducibility. Translational progress will benefit from harmonized in vivo models, full formulation reporting—size, polydispersity index (PDI), zeta potential, loading, and release—Good Manufacturing Practice (GMP)-compatible scale-up, and region-adapted regulatory guidance.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102575"},"PeriodicalIF":1.7,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Zhangyanming tablet treating dry eye disease: A prospective, open-label, randomized controlled trial","authors":"Hong-bin Xie ,&nbsp;Yuan Zhang ,&nbsp;Jun-hong Guo ,&nbsp;Ming-min Yang ,&nbsp;Jia-jia Hu ,&nbsp;Jie-wen Zhou ,&nbsp;Da-hui Ma","doi":"10.1016/j.eujim.2025.102574","DOIUrl":"10.1016/j.eujim.2025.102574","url":null,"abstract":"<div><h3>Introduction</h3><div>Dry eye disease (DED) is a chronic ocular surface disease that seriously affects quality of life. Traditional Chinese medicine (TCM) has prominent advantages in the treatment of DED. This study investigated the efficacy and safety of Chinese medicine Zhangyanming tablets (ZYMT) combined with fluorometholone eye drops (FED) and human epidermal growth factor eye drops (HEGFED) in the treatment of DED.</div></div><div><h3>Methods</h3><div>This was a randomized controlled study. A total of 122 patients with DED were randomly divided into the intervention group (<em>n</em> = 61) and the control group (<em>n</em> = 61). The control group received FED and HEGFED treatment (one drop twice daily), while the intervention group was given ZYMT (0.84 g orally, three times daily) in addition to the control group’s treatment. Both groups underwent 8 weeks of treatment. The primary outcome was the efficacy rate. The secondary outcomes included the mean change from baseline in the OSDI score and its subscales, tear film breakup time (BUT) and Schirmer’s test.</div></div><div><h3>Results</h3><div>After 8 weeks of treatment, the efficacy rate was 75.9 % (44/58) in the intervention group versus 54.2 % (32/59) in the control group (absolute difference 21.6 %, 95 % CI, 4.3 %∼37.2 %; risk ratio 1.40). The mean change from baseline in the OSDI score in the intervention group were significantly greater than those in the control group in week 8 (absolute difference -6.25, 95 % CI, -9.08∼-3.42). The mean changes from baseline in BUT, Schirmer’s test were significantly greater in the intervention group than that of the control group in both week 4 (BUT: absolute difference 2.49 s, 95 % CI, 1.82∼3.15 s; Schirmer’s test: absolute difference 1.11 mm/5 min, 95 % CI, 0.28∼1.95 mm/5 min) and week 8 (BUT: absolute difference 2.93 s, 95 % CI, 2.37∼3.49 s; Schirmer’s test: absolute difference 4.36 mm/5 min, 95 % CI, 3.88∼4.84 mm/5 min). No significant difference was observed in the safety profiles in these two groups (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>Compared to using FED and HEGFED alone, combined intervention of ZYMT can effectively ameliorate the eye symptoms of DED patients, and improve the efficacy rate.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"80 ","pages":"Article 102574"},"PeriodicalIF":1.7,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}